Yale Cancer Center (YCC) has launched the Yale Center for Immuno-Oncology (YCIO), which will build on YCC’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between YCC and immunobiology at Yale University.

“This new center gives us the chance to work more collaboratively and efficiently with our world-renowned scientists and faculty to address scientific questions in immuno-oncology,” says Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, associate director for translational research at YCC, and chief of medical oncology at YCC and Smilow Cancer Hospital. “We hope we can transform the way we treat people affected by cancer by generating research advances more quickly.” Herbst will serve as interim director until a search for a permanent director is completed.

“The addition of YCIO continues our goal to expand the depth and breadth of our science, including the broadening of our translational research infrastructure,” said Charles S. Fuchs, MD, MPH, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology) and director of YCC.

Goals for YCIO include building upon Yale’s leadership in immunobiology and immunotherapy drug development, developing the next generation of immune-based therapies, and genetically engineering immune cells to target cancers.